PDCD1 and hepatocellular carcinoma: ICIs that target either programmed cell death protein 1 (PD-1) or programmed death ligand 1 (PD-L1) have revolutionized the way that HCC is treated and are currently the mainstay of the majority of systemic treatments used in clinical practice and research [53].